Germany Cell and Gene Therapy Market Size, Share, Growth, Trends, and Industry Analysis: By Indication (Oncological Disorders, Genetic Disorders, Cardiovascular Disorders, Neurological Disorders, and Others), By Therapy Type (Gene Therapy and Cell Therapy), By End-User (Hospitals, Academic & Research Institutes, Cancer Care Centers, and Others) and Country

Germany cell and gene therapy market size was valued at US$ 427.9 million in 2023 and is projected to reach a value of US$ 3,354.4 million by 2030, at a CAGR of 34.2% from 2024-2030. Gene therapy consists of the transfer of genetic material, generally in a carrier or vector, and the uptake of the gene into the relevant cells of the body. Gene therapy helps treat diseases by substituting, inactivating, or introducing genes into cells in-vivo or in vitro. Cell and gene therapies are an innovative new class of drugs whose overall view is just starting.

Cell therapy helps to treat diseases by re-establishing or changing certain groups of cells or by consuming cells to carry a therapy through the body. The limited number of adoptions, cell, and gene therapy companies is attracting increasing public and private investment is driving the market growth. However, the complexity of cells and genes and treatment, comparatively low manufacturing volumes, and a large number of hand influences include current methods and cell therapies are high-cost to manufacture.

Key Players

The major players in the German cell and gene therapy market include Bayer AG, Roche Holding AG, Novartis AG, Spark Therapeutics, Bristol-Myers Squibb, CureVac AG, MolMed S.p.A., Miltenyi Biotec, BioNTech SE, and Vivebiotech. Most of these companies are highly engaged in the development of novel therapies, research collaboration with institutes, and investment into cutting-edge technologies to expand their portfolio in the dynamic sector.

Bayer AG, BioNTech SE, and Roche Holding AG are the three market leaders in the German market of cell and gene therapy. Bayer AG is considered one of the major companies mainly due to its high focus on research and development in rare genetic diseases by making the fullest utilization of its resources to produce novel solutions. BioNTech SE has revolutionary mRNA technology, which began to rapidly evolve into gene therapy applications, especially in the context of oncology, following the success of COVID-19 vaccines. Biotechnologies Swiss-based Roche Holding AG is a leader in biotechnology, having put great investment in gene therapy through the acquisition of Spark Therapeutics and a wholehearted commitment to personalized medicine with a robust pipeline of therapies.

Key Takeaways

• Based on the indication, the cardiovascular segment holds a 32.8% market share of cell and gene therapy in Germany.
• Based on the therapy type, the cell therapy segment holds 56.4% market share
• Based on the end-user, hospitals segment holds 41.3% market share

Facts & Figures

• April 2023: Over 60 clinical trials for gene therapies were reported to be active in Germany, focusing on various conditions such as genetic disorders and cancers.
• June 2022: The German government allocated €250 million in funding for research and development of cell and gene therapies as part of its national health strategy
• March 2023: Germany had more than 30 biotech companies actively developing cell and gene therapies, showcasing a robust innovation ecosystem

Key Developments

• In January 2024: Bayer AG is expected to report results from its ongoing clinical trials for a gene therapy targeting specific rare genetic conditions, aiming for regulatory submission by mid-year.
• In March 2024: BioNTech SE plans to initiate a clinical trial for its novel mRNA-based gene therapy aimed at treating a rare form of muscular dystrophy.
• In September 2024: Novartis AG is projected to expand its gene therapy portfolio by introducing a hemophilia treatment, pending regulatory approval.

Germany Cell and Gene Therapy Market Segmentation

By Indication: According to indication, the global cell and gene therapy market is divided into oncological, genetic, cardiovascular, neurological disorders and others. The oncological disorders segment held the largest market revenue share in terms of research and treatments in the biomedical areas of cell therapy and gene therapy. Both treatments can decrease the underlying cause of hereditary disorders and reduce the disease. The genetic disorder segment is likely to hold the highest growth rate over the period. This is because of factors such as the high incidence of genetic and chronic disease cases and developing government activities regarding increased public information about genetic diagnosis and testing.

By Therapy Type: Cell and gene therapy The global market for cell and gene therapy can be further segmented into cell and gene therapy. Under the segment of cell therapy held the highest market share. Potential applications in the field of cell therapy for the treatment of autoimmune diseases, cancers, and urinary problems are driving the cell therapy segments. Cell therapy is the process of introducing new, healthy cells into the body to substitute for diseases or damaged ones, to control the role of the patient's cell by the emergence of problems or by the extinction of the disease. The gene therapy segment led the pack during the historical period and is forecasted to occupy the second biggest market share. Gene therapy is one of those fields of medication that finds its focus on changing the genetic makeup in a disease-fighting effort or, rather, in disease reversal through the rectification of damaged genetic materials.

By End-User: Based on the end-user, the global cell and gene therapy market can be divided into hospitals, academic& research institutes, cancer care centers, and others. Among those, based on the highest share during the forecast period, is held by the hospital segment.